Moreover, imatinib inhibits the activity PDGFRβ [41] and suppresses that of TEL-PDGFRβ, which is a fusion tyrosine kinase generated in chronic myeloproliferative diseases [42]. Here, ETV6 is linked to myeloproliferative neoplasm.